Marshall Wace, LLP Aerie Pharmaceuticals Inc Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$4.95 - $9.16 $1.51 Million - $2.8 Million	305,951 Added 237.96%	434,525 $3.26 Million
Q1 2022 May 16, 2022	BUY	$5.64 - $9.8 $725,157 - $1.26 Million	128,574 New	128,574 $1.17 Million
Q2 2020 Aug 13, 2020	SELL	$12.0 - $16.13 $289,980 - $389,781	-24,165 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$11.84 - $25.52 $286,113 - $616,690	24,165 New	24,165 $326,000
Q2 2019 Aug 14, 2019	SELL	$28.97 - $48.21 $245,375 - $408,338	-8,470 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$36.32 - $49.25 $167,507 - $227,141	-4,612 Reduced 35.25%	8,470 $402,000
Q4 2018 Feb 14, 2019	BUY	$33.0 - $60.04 $431,706 - $785,443	13,082 New	13,082 $472,000
Q2 2018 Aug 14, 2018	SELL	$47.85 - $70.45 $296,670 - $436,790	-6,200 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$51.15 - $61.0 $317,130 - $378,200	6,200 New	6,200 $336,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.